Ospedale San Raffaele (OSR) is a private research hospital recognized by the Italian Ministry of Health. It comprises clinical, research and training activities, conducted in a highly specialized and qualified campus with 1340 beds, around 1600 basic, clinical and translational scientists, and almost 3000 students. OSR is one of the leading private scientific research institutes in Italy and performs cutting-edge science and aims at advancing the knowledge about human diseases and novel therapies through translational research. OSR can count on 4 Research Divisions, 4 Research Institutes, 4 Research Centers and more than 50 Clinical Operative Units.

OSR integrates its research with the education and training activities conducted at the Vita-Salute San Raffaele University (UniSR), which comprises the faculties of Medicine and Surgery, Psychology and Philosophy and provides specialized post graduate courses, residency programs in various medical specialties, and international PhD programs.

OSR and UniSR are completed by the Centro San Raffaele Foundation (FCSR), a non-profit organization that has been established to support the research of the San Raffaele Hospital with the aim of helping the development of science in the service of medicine. The relationship between OSR, UniSR and FCSR is managed by Master Agreements. A common campus hosts all teaching, basic, translational and clinical research activities in a large infrastructural compound. Therefore, OSR offers the opportunity to work in a unique environment where research laboratories, clinical units, and teaching activities effectively interact on a daily basis.

OSR is also part of a bigger health private group, the largest in Italy, one of the largest in Europe: San Donato Group (GSD). The Group consists of 18 hospitals of which 3 are IRCCS research hospitals with a total of 5169 beds and an amount of 3.9 million patients per year.

People – staff at OSR involved within INCITE


Dr. Andrea Brendolan  is a Group Leader in the Division of Experimental Oncology since 2008. He obtained his Master degree in Pharmacology in 1995 and a PhD in Developmental Immunology in 2005. He trained at Stanford University (1998-2001), Weill Cornell Medical Center in New York (2002-2007) and at RIKEN Reseach Institue for Allergy and Immunology (2007-2008). His research interests focus on understanding origin and acquisition of lymphoid stromal diversity, and the role of lymphoid stroma in regulating tumor progression. In parallel, his laboratory is translating basic information on how lymphoid tissues develop to generate of artificial lympho-organs for pre-clinical applications in cancer.

Dr. Vincenzo Russo, M.D. is a Group Leader in the Division of Experimental Oncology since 2007. He graduated in 1991 in Medicine and Surgery and obtained the specialization in Surgical Oncology in 1997. He received his training in cancer immunology and immunotherapy at the San Raffaele Scientific Institute and at Istituto di Ricerche Farmacologiche “Mario Negri” in Milan. Vincenzo Russo has been President of the Network Italiano per la Bioterapia dei Tumori (NIBIT), and is one of the founder member of the European Network for Cancer Immunotherapy (ENCI). His research interests focus on developing strategies to enhance the antitumor immune responses in cancer patients by modulating antigen presenting cells in vivo. Recently, his laboratory is investigating mechanisms of tumor immune evasion based on the manipulation of LXR/cholesterol metabolic pathways.